This simple amino acid supplement greatly reduces Alzheimer’s damage – ScienceDaily

Alzheimer’s disease (AD) is a progressive brain disorder and a leading cause of dementia worldwide. Despite years of research, there is still no cure. New antibody-based treatments that target amyloid β (Aβ) have recently emerged, but their benefits have been modest. These therapies can also be expensive and may trigger immune-related side effects, underscoring the urgent need for safer, more affordable options that can slow the disease.
A recent study published in Neurochemistry International offers a surprising possibility. Researchers from Kindai University and partner institutions found that arginine, a naturally occurring amino acid, can reduce the buildup of harmful Aβ proteins in animal models of Alzheimer’s. Arginine also acts as a safe chemical chaperone, helping proteins maintain their proper structure.
The team noted that while arginine is widely available as an over-the-counter supplement, the doses and methods used in this study were specifically designed for research and are not the same as commercial products.
The research group included Graduate Student Kanako Fujii and Professor Yoshitaka Nagai from the Department of Neurology at Kindai University Faculty of Medicine in Osaka, along with Associate Professor Toshihide Takeuchi from the Life Science Research Institute at Kindai University.
Lab and Animal Studies Show Strong Effects
In laboratory experiments, the scientists first showed that arginine can block the formation of Aβ42 aggregates, which are considered especially toxic. The effect increased with higher concentrations.
They then tested oral arginine in two well-established Alzheimer’s models:
In both cases, arginine treatment reduced the accumulation of Aβ and lessened its harmful effects.
"Our study demonstrates that arginine can suppress Aβ aggregation both in vitro and in vivo," explains Prof. Nagai. "What makes this finding exciting is that arginine is already known to be clinically safe and inexpensive, making it a highly promising candidate for repositioning as a therapeutic option for AD."
Improved Brain Health and Reduced Inflammation
In the mouse model, the benefits went beyond reducing protein buildup. Arginine lowered amyloid plaque levels and reduced the amount of insoluble Aβ42 in the brain. Treated mice also performed better in behavioral tests.
The researchers found that arginine reduced the activity of genes linked to pro-inflammatory cytokines, which are associated with neuroinflammation, a major feature of Alzheimer’s disease. This suggests that arginine may not only prevent harmful protein aggregation but also protect brain cells more broadly.
"Our findings open up new possibilities for developing arginine-based strategies for neurodegenerative diseases caused by protein misfolding and aggregation," notes Prof. Nagai. "Given its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimer’s and potentially other related disorders."
A Low-Cost Path Toward New Alzheimer’s Treatments
The study highlights the growing interest in drug repositioning, which involves finding new uses for existing, well-established compounds. Because arginine is already used clinically in Japan and has been shown to safely reach the brain, it could bypass some of the early hurdles that slow down traditional drug development.
Still, the researchers caution that more work is needed. Additional preclinical and clinical studies will be required to determine whether these results can be reproduced in humans and to establish the most effective dosing strategies.
Even so, the findings provide strong early evidence that simple nutritional or pharmacological approaches may help reduce amyloid buildup and improve brain function.
Expanding Understanding of Alzheimer’s Biology
Beyond its potential as a treatment, this work sheds new light on how Aβ proteins form and accumulate in the brain. It also points to a practical and cost-effective strategy that could eventually benefit millions of people living with Alzheimer’s worldwide.
Professor Yoshitaka Nagai, a neurologist and Chair of the Department of Neurology at Kindai University Faculty of Medicine in Osaka, focuses his research on neurodegenerative diseases including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis. His work centers on protein misfolding and RNA-related mechanisms, and he has received multiple honors from organizations such as the Japanese Society of Neurochemistry and the Japanese Dementia Society.
This research was supported by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) (Grant No. 20H05927), Japan Society for the Promotion of Science (JSPS) (Grant Nos. 24H00630, 21H02840, 22H02792, and 25K02432), Japan Science and Technology Agency (JST) Super-Highway Program (SHW2023-03), and National Center of Neurology and Psychiatry.
Story Source:
Materials provided by Kindai University. Note: Content may be edited for style and length.
Journal Reference:
Cite This Page:
A Simple Molecule Could Unlock Safer, Easier Weight Loss
Researchers Unveil Groundbreaking Sustainable Solution to Vitamin B12 Deficiency
Darwin’s Islands Still Evolving: Giant Daisies Rewrite the Rules of Evolution
Beyond Inflammation: Scientists Uncover New Cause of Persistent Rheumatoid Arthritis
Stay informed with ScienceDaily’s free email newsletter, updated daily and weekly. Or view our many newsfeeds in your RSS reader:
Keep up to date with the latest news from ScienceDaily via social networks:
Tell us what you think of ScienceDaily — we welcome both positive and negative comments. Have any problems using the site? Questions?

source